WALTHAM -
SPY001 is a fully optimized and half-life extended antibody targeting 47 and SPY002 is a fully optimized and half-life extended antibody targeting TL1A, both in development for the treatment of IBD.
We are thrilled to share preclinical findings supporting our two lead programs, SPY001 and SPY002, during the
The posters will be available for viewing during the
Title: Development and Characterization of a Novel Extended Half-Life Monoclonal Antibody Drug Candidate Targeting Integrin 47 for the Treatment of IBD
Authors:
Title: A Novel Monoclonal Antibody Drug Candidate SPY001 Targeting Integrin 47 for the Treatment of IBD Demonstrates Prolonged Half-Life in Non-Human Primates
Authors:
Title: Development and Characterization of SPY002, a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting TL1A for the Treatment of IBD
Authors:
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre s pipeline includes extended half-life antibodies targeting 47, TL1A, and IL-23.
Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute forward-looking statements within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Spyre and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Spyre s management team s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, Spyre s ability to achieve the expected benefits or opportunities with respect to its pipeline of product candidates such as potential improved dosing regimens of SPY-001 and SPY-002 over approved product candidates, Spyre s preclinical and future clinical development activities, the potential therapeutic benefits and economic value of Spyre s product candidates, and the timing and results of preclinical studies and clinical trials. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words opportunity, potential, milestones, pipeline, can, goal, aim, strategy, target, seek, anticipate, achieve, believe, contemplate, continue, could, estimate, expect, intends, may, might, plan, possible, predict, project, should, will, would and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Spyre will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Spyre s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited those uncertainties and factors described under the heading Risk Factors and Note about Forward-Looking Statements in Spyre s most recent Quarterly Report on Form 10-Q filed with the
Contact:
Email: Eric.mcintyre@spyre.com
(C) 2024 Electronic News Publishing, source